CA3268201A1 - Utilisation de suspensions injectables de propionate de fluticasone à action prolongée pour le traitement et la prévention d'inflammations du tractus gastro-intestinal - Google Patents

Utilisation de suspensions injectables de propionate de fluticasone à action prolongée pour le traitement et la prévention d'inflammations du tractus gastro-intestinal

Info

Publication number
CA3268201A1
CA3268201A1 CA3268201A CA3268201A CA3268201A1 CA 3268201 A1 CA3268201 A1 CA 3268201A1 CA 3268201 A CA3268201 A CA 3268201A CA 3268201 A CA3268201 A CA 3268201A CA 3268201 A1 CA3268201 A1 CA 3268201A1
Authority
CA
Canada
Prior art keywords
injections
pharmaceutical composition
corticosteroid
esophagus
ring
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3268201A
Other languages
English (en)
Inventor
James Helliwell
Amanda Malone
Murray Webb
James Price
Troy Loss
Nicola Price
Paul Brennan
Original Assignee
Eupraxia Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eupraxia Pharmaceuticals Inc filed Critical Eupraxia Pharmaceuticals Inc
Publication of CA3268201A1 publication Critical patent/CA3268201A1/fr
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

ABRÉGÉ L'invention concerne des méthodes de traitement ou de prévention de maladies inflammatoires du tractus gastro-intestinal (GI) par administration locale d'une composition pharmaceutique contenant une composition à libération prolongée formulée pour permettre une libération prolongée d'un corticostéroïde dans le tissu GI.
CA3268201A 2022-10-04 2023-10-03 Utilisation de suspensions injectables de propionate de fluticasone à action prolongée pour le traitement et la prévention d'inflammations du tractus gastro-intestinal Pending CA3268201A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263413167P 2022-10-04 2022-10-04
US63/413,167 2022-10-04
PCT/US2023/075874 WO2024077017A1 (fr) 2022-10-04 2023-10-03 Utilisation de suspensions injectables de propionate de fluticasone à action prolongée pour le traitement et la prévention d'inflammations du tractus gastro-intestinal

Publications (1)

Publication Number Publication Date
CA3268201A1 true CA3268201A1 (fr) 2024-04-11

Family

ID=88695541

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3268201A Pending CA3268201A1 (fr) 2022-10-04 2023-10-03 Utilisation de suspensions injectables de propionate de fluticasone à action prolongée pour le traitement et la prévention d'inflammations du tractus gastro-intestinal

Country Status (9)

Country Link
EP (1) EP4598506A1 (fr)
JP (1) JP2025533837A (fr)
KR (1) KR20250091219A (fr)
CN (1) CN119968199A (fr)
AU (1) AU2023356957A1 (fr)
CA (1) CA3268201A1 (fr)
IL (1) IL319996A (fr)
MX (1) MX2025003653A (fr)
WO (1) WO2024077017A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240424000A1 (en) * 2023-06-26 2024-12-26 Eupraxia Pharmaceuticals Inc. Long-acting intra-articular dosage forms containing fluticasone propionate and use thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63122620A (ja) 1986-11-12 1988-05-26 Sanraku Inc ポリ乳酸マイクロスフエア及びその製造方法
PH30995A (en) 1989-07-07 1997-12-23 Novartis Inc Sustained release formulations of water soluble peptides.
EP0535937B2 (fr) 1991-10-01 2008-05-21 Takeda Chemical Industries, Ltd. Préparation à base de microparticules à libération prolongée et production de celle-ci
EP1585500B8 (fr) 2002-12-20 2017-07-26 Auritec Pharmaceuticals Particules enrobees destinees a l'administration prolongee d'ingredients pharmaceutiques
EP3970726A1 (fr) * 2010-06-24 2022-03-23 ViroPharma Biologics LLC Procédés de traitement de l'inflammation de l' sophage
BR112015024234B1 (pt) 2013-03-21 2022-11-16 Eupraxia Pharmaceuticals USA LLC Composição farmacêutica de liberação sustentada injetável, uso da mesma para diminuir inflamação ou controlar dor e método para formar micropartículas revestidas
WO2016205172A1 (fr) * 2015-06-15 2016-12-22 Banner Life Sciences Llc Pastilles molles comprenant des corticostéroïdes
US20220168665A1 (en) 2019-04-10 2022-06-02 Eupraxia Pharmaceuticals Inc. Process for making drug crystals of desired size distribution and morphology

Also Published As

Publication number Publication date
KR20250091219A (ko) 2025-06-20
AU2023356957A1 (en) 2025-03-27
EP4598506A1 (fr) 2025-08-13
IL319996A (en) 2025-06-01
WO2024077017A1 (fr) 2024-04-11
JP2025533837A (ja) 2025-10-09
CN119968199A (zh) 2025-05-09
MX2025003653A (es) 2025-07-01

Similar Documents

Publication Publication Date Title
US20250090467A1 (en) Injectable sustained release composition and method of using the same for treating inflammation in joints and pain associated therewith
US9980902B2 (en) Method for treating intestinal fibrosis
RU2681835C2 (ru) Лекарственные формы нейроактивных стероидов и способы лечения нарушений цнс
CN117715625A (zh) 用于治疗晶体和非晶体相关急性炎症性关节炎的包含秋水仙碱的关节内注射用剂型
CN121013711A (zh) 用于治疗关节病诸如骨关节炎的包含秋水仙碱的关节内注射剂型
AU2023356957A1 (en) Use of long-acting fluticasone propionate injectable suspensions for treating and preventing inflammations of the gastrointestinal tract
CN118891032A (zh) 用于延长释放非诺贝特的微球
JP2006028031A (ja) 経粘膜吸収用薬物封入ナノ粒子
US20190274950A1 (en) Modified release formulations of mycophenolate mofetil
EP4321183A1 (fr) Enrobage de médicament, saccule d'enrobage de médicament et son procédé de préparation
CN112121028B (zh) 一种辛伐他汀固体纳米粒制剂及其制备方法
CN117717524B (zh) 一种负载精氨酸的白蛋白基缓释微球及其制备方法与应用
JP2000143538A (ja) 免疫調節剤を含有する医薬組成物
HK40072275A (en) Injectable sustained release composition and method of using the same for treating inflammation in joints and pain associated therewith
HK1219433B (en) Injectable sustained release composition and method of using the same for treating inflammation in joints and pain associated therewith

Legal Events

Date Code Title Description
A00 Application filed

Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A00-A101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION RECEIVED - PCT

Effective date: 20250319

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W200 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST OR RESPONSE SUBMITTED ONLINE

Effective date: 20250319

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250319

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST TO REGISTER A DOCUMENT RECEIVED

Effective date: 20250319

A00 Application filed

Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A00-A102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: COMPLIANCE REQUIREMENTS DETERMINED MET

Effective date: 20250623

A15 Pct application entered into the national or regional phase

Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A15-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: NATIONAL ENTRY REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250623

P18 Priority claim added or amended

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P18-P105 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRIORITY CLAIM REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250623

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250623

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REGISTER A DOCUMENT REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250623

P22 Classification modified

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P22-P110 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CLASSIFICATION MODIFIED

Effective date: 20250625

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD

Year of fee payment: 2

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250926

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250926